According to the IDF Diabetes Atlas, in 2021, about 61 million adults aged from 20 to 79 years were living with diabetes in the Europe. Besides, Europe has the highest number of children and adolescents with type 1 diabetes, accounting for 295,000 in total.
Europe biomarker technologies market is segmented into test type, technology, product, indication, end user, application, and country. Based on indication, the market can be segmented into oncology, infectious diseases, autoimmune disorders, cardiovascular disorders and others. Among them, the cardiovascular disorders segment is expected to undergo fastest CAGR during the forecast period owing to rise in number of people suffering from cardiovascular diseases.
Based on application, Europe biomarker technologies market is segmented into clinical diagnostics, research and drug discovery & development. Among these, the drug discovery segment is expected to witness significant growth through 2028 as biomarker technologies are helpful in drug discovery particularly for cancer and cardiovascular diseases.
Major players operating in the Europe biomarker technologies market are F. Hoffmann-La Roche AG, Merck KGAA, Beckman Coulter, Inc., Qiagen N.V., Biomérieux SA, Bio-Rad Laboratories N.V., Siemens AG, Abbott Molecular Inc., Danaher Corporation, and Epigenomics AG. The companies are undergoing growth strategies such as mergers & acquisitions and product innovation.
Objective of the Study
- To analyze and estimate the market size of Europe biomarker technologies market from 2018 to 2021.
- To estimate and forecast the market size of Europe biomarker technologies market from 2022 to 2028 and growth rate until 2028.
- To classify and forecast Europe biomarker technologies market based on test type, technology, product, indication, end user, application, company, and country.
- To identify dominant country or segment in the Europe biomarker technologies market.
- To identify drivers and challenges for Europe biomarker technologies market.
- To examine competitive developments such as expansions, mergers & acquisitions, etc., in Europe biomarker technologies market.
- To identify and analyze the profile of leading players operating in Europe biomarker technologies market.
- To identify key sustainable strategies adopted by market players in Europe biomarker technologies market.
Download Free Sample Report
Market insights research performed both primary as well as exhaustive secondary research for this study. Initially, Market insights research sourced a list of biomarker technologies companies across Europe. Subsequently, Market insights research conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, Market insights research could include the companies who could not be identified due to the limitations of secondary research. Market insights research analyzed the presence of all major players across Europe.
Market insights research calculated the market size of
Key Target Audience
- Biomarker technology companies, vendors, end users and other stakeholders
- Government bodies such as regulating authorities and policy makers
- Organizations, forums, and alliances related to biomarker technologies
- Market research and consulting firms
The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as
| Attribute | Details |
| Base Year | 2022 |
| Historic Data | 2018 – 2021 |
| Estimated Year | 2023 |
| Forecast Period | 2024 – 2028 |
| Quantitative Units | Revenue in USD Million and CAGR for 2018-2022 and 2023-2028 |
| Report coverage | Revenue forecast, company share, competitive landscape, growth factors, and trends |
| Segments covered | · Test Type · Technology · Product · Indication · End User · Application |
| Country scope | Italy; France; United Kingdom; Germany; Spain; Belgium; Netherlands |
| Key companies profiled | F. Hoffmann-La Roche AG, Merck KGAA, Beckman Coulter, Inc., Qiagen N.V., Biomérieux SA, Bio-Rad Laboratories N.V., Siemens AG, Abbott Molecular Inc., Danaher Corporation, and Epigenomics AG. |
| Customization scope | 10% free report customization with purchase. Addition or alteration to country, & segment scope. |
| Pricing and purchase options | Avail customized purchase options to meet your exact research needs. Explore purchase options |
| Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
